Related Experiment Videos
Resistance to growth inhibition by transforming growth factor-beta in malignant glioma cells with functional
1Department of Neurosurgery, Yamanashi Medical University, Japan.
Object:
The aim of this study was to investigate the mechanism by which malignant glioma cells escape from growth inhibition mediated by transforming growth factor-beta (TGF-beta), a ubiquitous cytokine that inhibits cell proliferation by causing growth arrest in the G1 phase of the cell cycle.
Methods:
The authors measured the response of eight malignant glioma cell lines to the growth-inhibiting activity of TGF-beta in vitro and the expression of TGF-beta Types I and II receptors in malignant glioma cells. The effect of TGF-beta on the expression of a p27Kip1 cyclin-dependent kinase inhibitor was also investigated to assess the downstream signal transmission from TGF-beta receptors. All malignant glioma cell lines were insensitive to growth inhibition by TGF-beta1 and TGF-beta2. Analyses of TGF-beta receptors by means of affinity labeling in which 125I-TGF-beta1 was used showed that six glioma lines had both TGF-beta Types I and II receptors on their cell surfaces, whereas two lines had very small amounts of TGF-beta Type I and/or Type II receptors. Northern blot analysis showed that all tumor lines expressed variable levels of messenger RNAs for both TGF-beta Types I and II receptors. Flow cytometric analyses revealed that treatment of malignant glioma cells with TGF-beta1 significantly downregulated the expression of p27Kip1 protein in all malignant glioma cell lines except one.
Conclusions:
The authors suggest that most malignant glioma cells express TGF-beta Types I and II receptors, which can transmit some signals downstream and that the loss of response to TGF-beta growth inhibition may not be caused by an abnormality of the TGF-beta receptors.
Insights
Malignant glioma cells resist growth inhibition by transforming growth factor-beta (TGF-beta), despite expressing TGF-beta receptors. This suggests resistance mechanisms lie beyond receptor abnormalities.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Transforming growth factor-beta (TGF-beta) is a cytokine that typically inhibits cell proliferation by arresting the cell cycle.
- Malignant gliomas often exhibit resistance to TGF-beta-mediated growth inhibition, a critical factor in tumor progression.
Purpose of the Study:
- To investigate the molecular mechanisms underlying malignant glioma cell resistance to TGF-beta growth inhibition.
- To determine the role of TGF-beta receptor expression and downstream signaling in this resistance.
Main Methods:
- Assessed the in vitro response of eight malignant glioma cell lines to TGF-beta.
- Quantified TGF-beta Types I and II receptor expression using affinity labeling and Northern blot.
- Evaluated the effect of TGF-beta on p27Kip1 protein expression via flow cytometry.
Main Results:
- All tested glioma cell lines were insensitive to TGF-beta1 and TGF-beta2 growth inhibition.
- Most glioma lines expressed both TGF-beta Types I and II receptors, with variable mRNA levels.
- TGF-beta treatment downregulated p27Kip1 protein in most cell lines, indicating some downstream signaling.
Conclusions:
- Malignant glioma cells frequently express functional TGF-beta receptors capable of downstream signaling.
- Resistance to TGF-beta growth inhibition in these cells is unlikely due to a complete lack of or abnormality in TGF-beta receptors.